Purpose To update the 2003 American Society of Clinical Oncology technology assessment
on adjuvant use of aromatase inhibitors. Recommendations Based on results from multiple …

OBJECTIVE: To conduct an evidence-based technology assessment to determine whether
the routine use of anastrozole or any of the aromatase inhibitors in the adjuvant breast cancer …

Purpose: To compare the efficacy of a standard anthra-cycline-based regimen to a dose-intensified
anthracycline regimen in locally advanced breast cancer. Patients and Methods: …

Purpose: To compare the clinical features, natural history, and outcomes for women with “triple-negative”
breast cancer with women with other types of breast cancer. Experimental …

… Ki-67 level as a marker of proliferation is also important for this distinction [23]. Both of these
… substitute for high Ki-67 for this purpose. The Panel noted that standardized cut-offs for Ki-67 …

Background Resistance to endocrine therapy in breast cancer is associated with activation of
the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies…

Background In hormone-dependent breast cancer, five years of postoperative tamoxifen
therapy — but not tamoxifen therapy of longer duration — prolongs disease-free and overall …

… Ki-67 determination Extensive studies support the prognostic value of Ki-67, but clinical …
cut point, at least to predict pCR along the continuum of Ki-67 levels [71, 72]. International …

Background The recurrence score based on the 21-gene breast cancer assay predicts
chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it …

Background The 21-gene recurrence score assay is prognostic for women with node-negative,
oestrogen-receptor-positive breast cancer treated with tamoxifen. A low recurrence score …